Core Viewpoint - The Chinese innovative pharmaceutical sector is entering a golden development period, presenting a once-in-a-century investment opportunity due to unmet global medical needs and significant advancements in the industry [4][9]. Group 1: Market Growth and Trends - In 2025, the total value of out-licensing (BD) transactions for Chinese innovative drugs reached $135.7 billion, a significant increase from $51.9 billion in 2024, with upfront payments rising to $7 billion from $4.1 billion [4][9]. - In January 2026 alone, the transaction volume reached $30 billion, with upfront payments of $3 billion, indicating a strong start to the year [4][9]. - The proportion of external procurement pipelines from China for multinational pharmaceutical companies surged from 10% in 2020 to 42% in 2025, highlighting China's growing importance in the global pharmaceutical landscape [4][9]. Group 2: Clinical Milestones and Innovations - 2026 is identified as a critical year for validating major drugs, with several key clinical milestones expected to emerge, potentially leading to a re-evaluation of industry value [5][9]. - Notable clinical trials include Kangfang Biotech's AK112 for non-small cell lung cancer, which is anticipated to redefine first-line treatment standards [5][9]. - The ADC sector is also poised for significant developments, with Kelong Botai's SKB264 and Baili Tianheng's BL-B01D1 expected to release important phase III clinical data [5][9]. Group 3: Impact on Related Industries - The CXO (Contract Research Organization) sector, closely tied to innovative pharmaceuticals, is expected to benefit from the technological advancements in drug development, leading to a recovery in industry sentiment [5][10]. - Companies within the "WuXi" ecosystem, such as WuXi Biologics and WuXi AppTec, are experiencing a resurgence in orders and performance, reaching historical highs despite previous unfavorable U.S. policies [10].

Group 1 - The U.S. Department of Defense unexpectedly released a new list of Chinese military companies, including Alibaba, BYD, Baidu, WuXi AppTec, and SUTENG, while removing Yangtze Memory Technologies from the list [1][3] - Shortly after its submission for public notice, the list was urgently retracted without any explanation, indicating a hasty and confused decision-making process [3] - This list, while not a direct sanction, would prevent the U.S. Department of Defense from collaborating with the listed companies, suggesting a politically motivated trial [3][4] Group 2 - The external perception is that this action was intended to create pressure ahead of Trump's visit to China in two months, but the execution was deemed too rushed, leading to a quick retraction [4]

Group 1 - Morgan Stanley increased its stake in WuXi AppTec (02359) by 942,132 shares at a price of HKD 116.0887 per share, totaling approximately HKD 109 million [1] - After the increase, Morgan Stanley's total shareholding in WuXi AppTec is approximately 35,774,200 shares, representing a 7% ownership stake [1]

智通财经APP获悉，香港联交所最新数据显示，2月9日，摩根大通增持药明康德(02359)94.2132万股， 每股作价116.0887港元，总金额约为1.09亿港元。增持后最新持股数目约为3577.42万股，持股比例为 7%。 ...

Core Insights - The article highlights the AH premium rates of various companies, with Northeast Electric (00042) leading at 785.25% and Ningde Times (03750) at the bottom with -14.36% [1] - The article also discusses the deviation values of these stocks, indicating significant discrepancies between their A-shares and H-shares [1] AH Premium Rate Rankings - Northeast Electric (00042) has the highest AH premium rate at 785.25%, followed by Sinopec Oilfield Service (01033) at 296.70% and Beijing Jingcheng Machinery Electric (00187) at 286.85% [1] - The lowest AH premium rates are recorded for Ningde Times (03750) at -14.36%, WuXi AppTec (02359) at -4.81%, and China Merchants Bank (03968) at -3.07% [1] Deviation Value Rankings - Beijing Jingcheng Machinery Electric (00187) has the highest deviation value at 22.00%, indicating a significant difference from its average premium rate [1] - The lowest deviation values are seen in Chenming Paper (01812) at -59.85%, Changfei Optical Fiber (06869) at -31.95%, and Junda Co., Ltd. (02865) at -27.72% [1] Additional Insights - The article provides a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, showcasing the performance of various companies in the market [1][2] - The data is generated based on the Hong Kong Stock Exchange and reflects the current market conditions as of February 13 [2]

Company and Industry Summary Company: WuXi AppTec (药明康德) Key Points - **Revenue Growth**: WuXi AppTec has announced a revenue forecast for 2025 of 45.46 billion yuan, representing a year-on-year increase of 15.8%. The revenue from continuing operations is expected to grow at a rate of 21.4% [1] - **Guidance vs. Actuals**: The company's guidance for 2025 was between 43.5 billion and 44 billion yuan, with a growth rate for continuing operations projected at 17-18%. The actual forecast exceeds this guidance, indicating strong performance [1] - **Quarterly Performance**: In Q4 2025, the company is expected to maintain a sequential revenue growth, sustaining over 20% growth for the year despite a high base in Q4 2024. The Non-IFRS net profit margin for Q4 2025 is projected to be stable at 35.1%, slightly lower than Q3 2025 [1] Industry: TIDES and CDMO Key Points - **TIDES Business Growth**: The TIDES business is expected to see revenue growth exceeding 90% in 2025. With large orders anticipated in 2026, the Chemistry business is also expected to maintain rapid growth and an upward trend in gross margins. The recovery of domestic demand and stable overseas demand are likely to enhance profit margins further [2] - **Global Position in CDMO**: WuXi AppTec has established itself as a leading player in the global small molecule CDMO sector. In 2025, the company supported the approval of 8 out of 30 new small molecule drugs by the FDA. Additionally, it has supported 11 out of 56 peptides and 12 out of 36 small molecules in the global GLP-1 drug category [2] - **Potential Beneficiaries**: The company is positioned to be a major beneficiary of future high-potential drugs such as oral GLP-1 and siRNA, which are expected to see significant market uptake [2]

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 730.77%, Beijing Jingcheng Machinery Electric (00187) at 288.68%, and Sinopec Oilfield Service (01033) at 288.17% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -16.06%, WuXi AppTec (02359) at -7.28%, and China Merchants Bank (03968) at -4.68% [1][2] - The companies with the highest deviation values are Beijing Jingcheng Machinery Electric (00187) at 24.37%, Longpan Technology (02465) at 16.69%, and Cambridge Technology (06166) at 16.18% [1][3] Group 2 - The companies with the lowest deviation values are Northeast Electric (00042) at -85.40%, Junda Co., Ltd. (02865) at -56.63%, and Yangtze Optical Fibre and Cable (06869) at -52.47% [1][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) at 275.78% and Nanjing Panda Electronics (00553) at 237.14% [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) at -0.89% and Zijin Mining (02899) at 3.75% [2]

Core Viewpoint - Nomura's report indicates that WuXi AppTec's revenue is expected to grow by 9.2% year-on-year to 11.7 billion yuan in Q4 2025, with net profit increasing by 142% to 7.1 billion yuan [1] Financial Projections - For the fiscal year 2026, revenue is projected to grow by 16% year-on-year to 52.6 billion yuan, surpassing market expectations of 51.1 billion yuan due to strong performance in the chemical business [1] - Net profit for 2026 is expected to increase by 3% year-on-year to 19.6 billion yuan [1] Business Segment Performance - By business segment, revenue for TIDES and late-stage development and manufacturing is expected to grow by 55% and 10% year-on-year, reaching 17.1 billion yuan and 21.6 billion yuan respectively [1] - The growth in TIDES is supported by sustained demand and the company's large-scale functional production capacity of 100,000 liters [1] Target Price Adjustments - Nomura has raised the target price for WuXi AppTec's H-shares from 132.8 HKD to 157.07 HKD and for A-shares from 120.85 CNY to 142.93 CNY, maintaining a "Buy" rating [1]

Group 1 - The stock price of Reborn Biotech (06938.HK) increased by 13.65% [1] - WuXi Biologics (02269.HK) saw a rise of 4.83% in its stock price [1] - Baosai Tu-B (02315.HK) experienced a stock price increase of 3.88% [1] - WuXi AppTec (02359.HK) had a stock price growth of 3.15% [1]

Group 1 - The article highlights the top three companies with the highest AH premium rates: Northeast Electric (00042) at 831.03%, Beijing Jingcheng Machinery Electric (00187) at 291.45%, and Sinopec Oilfield Service (01033) at 288.17% [1] - The bottom three companies with the lowest AH premium rates are Contemporary Amperex Technology (03750) at -12.59%, WuXi AppTec (02359) at -4.58%, and China Merchants Bank (03968) at -4.48% [1] - The article provides a detailed ranking of the top ten and bottom ten AH stocks based on their premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Beijing Jingcheng Machinery Electric (00187) at 27.77%, Jinju Group (02009) at 19.35%, and Kai Sheng New Energy (01108) at 16.80% [1] - The bottom three companies with the most negative deviation values are Junda Co., Ltd. (02865) at -60.53%, Chenming Paper (01812) at -32.02%, and CNOOC Services (02883) at -31.42% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]